BioChaperone®, A versatile platform adapted to a wide range of proteins
To date, Adocia researchers have developed a portfolio of more than 300 BioChaperone® polymers, oligomers and small organic compounds. The main variations among BioChaperone® polymers are size, nature, and number of anionic and hydrophobic grafts. Thanks to this diversity, the BioChaperone® technology has already been applied to three main categories of proteins of different sizes and properties.
Insulin, a key hormone in the treatment of diabetes, has been combined with BioChaperone® to enhance its pharmacokinetics and pharmacodynamics.
Adocia is currently developing 4 insulin-based products using BioChaperone®:
- BioChaperone® Combo: A combination of prandial and basal insulin based on insulin glargine. BioChaperone technology makes it possible to mix both insulins by solubilizing insulin glargine at Neutral pH.
- BioChaperone® Lispro. This ultra-rapid insulin, licensed to Eli Lilly since December 2014, is being developed with the goal of optimizing glucose levels during and after meals.
- BioChaperone® Human Glucagon. Glucagon is another key metabolic hormone which role is schematically opposite to that of insulin. A healthy pancreas secretes both insulin and glucagon to keep blood glucose into a tight physiological range. However, human glucagon is a very unstable molecule and commercially available products may only be reconstituted ex temporane from a lyophilized powder. Using the BioChaperone® technology, Adocia aims to develop a stable aqueous solution of recombinant human glucagon, that may be used in varied settings, including the treatment of severe hypoglycaemia and the use in an artificial pancreas.
- HinsBet®, a BioChaperone® fast-acting human insulin, accelerates the pharmacokinetic profile of human insulin, aiming to obtain comparable performances to an insulin analog.